nf κb responsive promoter (Addgene inc)
Addgene inc is a verified supplier 
94
Structured Review
Addgene inc
nf κb responsive promoter
Nf κb Responsive Promoter, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psirv+nf+%CE%BAb+ecfp/pSIRV-NF-kB-eCFP+(Plasmid+%23118094)/pmc13043689-236-30-34
Average 94 stars, based on 6 article reviews
Nf κb Responsive Promoter, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psirv+nf+%CE%BAb+ecfp/pSIRV-NF-kB-eCFP+(Plasmid+%23118094)/pmc13043689-236-30-34
Average 94 stars, based on 6 article reviews
nf κb responsive promoter - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
Activation Assay:Article Title: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Article Snippet: Chimeric antigen receptor (CAR)-natural killer (NK) cell therapies hold promise for solid tumours but remain limited because of poor tumour infiltration, persistence and resistance in the tumour microenvironment.. Here, to identify gain-of-function targets that enhance CAR-NK cell efficacy, we performed an unbiased in vivo CRISPR activation screen followed by a barcoded targeted in vivo open reading frame screen in primary human CAR-NK cells.. We identified and comprehensively validated OR7A10, a G protein-coupled receptor (GPCR), as the top candidate. Construct:Article Title: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Article Snippet: Chimeric antigen receptor (CAR)-natural killer (NK) cell therapies hold promise for solid tumours but remain limited because of poor tumour infiltration, persistence and resistance in the tumour microenvironment.. Here, to identify gain-of-function targets that enhance CAR-NK cell efficacy, we performed an unbiased in vivo CRISPR activation screen followed by a barcoded targeted in vivo open reading frame screen in primary human CAR-NK cells.. We identified and comprehensively validated OR7A10, a G protein-coupled receptor (GPCR), as the top candidate. Plasmid Preparation:Article Title: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Article Snippet: Chimeric antigen receptor (CAR)-natural killer (NK) cell therapies hold promise for solid tumours but remain limited because of poor tumour infiltration, persistence and resistance in the tumour microenvironment.. Here, to identify gain-of-function targets that enhance CAR-NK cell efficacy, we performed an unbiased in vivo CRISPR activation screen followed by a barcoded targeted in vivo open reading frame screen in primary human CAR-NK cells.. We identified and comprehensively validated OR7A10, a G protein-coupled receptor (GPCR), as the top candidate. Generated:Article Title: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Article Snippet: Chimeric antigen receptor (CAR)-natural killer (NK) cell therapies hold promise for solid tumours but remain limited because of poor tumour infiltration, persistence and resistance in the tumour microenvironment.. Here, to identify gain-of-function targets that enhance CAR-NK cell efficacy, we performed an unbiased in vivo CRISPR activation screen followed by a barcoded targeted in vivo open reading frame screen in primary human CAR-NK cells.. We identified and comprehensively validated OR7A10, a G protein-coupled receptor (GPCR), as the top candidate. Polymerase Chain Reaction:Article Title: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Article Snippet: Chimeric antigen receptor (CAR)-natural killer (NK) cell therapies hold promise for solid tumours but remain limited because of poor tumour infiltration, persistence and resistance in the tumour microenvironment.. Here, to identify gain-of-function targets that enhance CAR-NK cell efficacy, we performed an unbiased in vivo CRISPR activation screen followed by a barcoded targeted in vivo open reading frame screen in primary human CAR-NK cells.. We identified and comprehensively validated OR7A10, a G protein-coupled receptor (GPCR), as the top candidate. |